Trial intelligence / Profile preview

Efficacy and safety of efavirenz in adult Niemann-Pick type C with cognitive impairment

2019-004498-18Phase 2Active

Sponsor: Dr. Jordi GascÃ³n / Dra. Lola Ledesma
Start: Dec 2019
Modality: Small Molecules
Countries: 1

Overview

Phase 2, single-arm trial of efavirenz in Niemann-Pick disease type C (NPC), sponsored by Dr. Jordi GascÃ³n / Dra. Lola Ledesma. Primary endpoint: Change in cognitive performance at 52 weeks. Started Dec 2019; status: active.

Drugs

efavirenz

Conditions

Niemann-Pick disease type C (NPC)

Beyond the preview

Go deeper on 2019-004498-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2019-004498-18.